Updates are available Correction dated 2022-06-22
Click to view Correction: https://doi.org/10.1007/s00280-022-04450-2
-
Authors
de Jong, Loek A. W. http://orcid.org/0000-0002-3989-8386
Elekonawo, Fortuné M. K.
Lambert, Marie
de Gooyer, Jan Marie
Verheul, Henk M. W.
Burger, David M.
de Wilt, Johannes H. W.
Chatelut, Etienne
ter Heine, Rob
de Reuver, Philip R.
Bremers, Andre J. A.
van Erp, Nielka P.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03364907 at ClinicalTrials.govDocuments that mention this clinical trial
Wide variation in tissue, systemic, and drain fluid exposure after oxaliplatin-based HIPEC: results of the GUTOX study
https://doi.org/10.1007/s00280-020-04107-y
- License Information
-
More Information
Article History
Received: 20 March 2020
Accepted: 24 June 2020
First Online: 27 June 2020
Change Date: 22 June 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00280-022-04450-2
Compliance with ethical standards
:
: Dr. Nielka van Erp declares the following financial activities outside the submitted work: received grants for investigator driven studies from Astellas and Janssen-Cilag and educational grants for lectures from Sanofi and Bayer. The other authors declare that they have no conflicts of interest.
: The GUTOX trial was approved by the institutional ethics committee Arnhem-Nijmegen (Nijmegen) and was compliant with the Declaration of Helsinki.
: All patients provided written informed consent before entering the study.
